Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 4/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.31 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.31 |
| ▸ | FAP | Q12884 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3871583 | 0.85 | DPP7 (0.32) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL9658849 | 0.83 | S1PR1 (0.49) | DPP4S1PR1S1PR3S1PR5S1PR4 | |
| SCHEMBL9660985 | 0.83 | S1PR1 (0.49) | DPP4S1PR1S1PR3S1PR5S1PR4 | |
| SCHEMBL15639189 | 0.83 | DPP4 (0.47) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL9660557 | 0.83 | S1PR1 (0.49) | DPP4S1PR1S1PR3S1PR5S1PR4 | |
| SCHEMBL9661749 | 0.83 | S1PR1 (0.49) | DPP4S1PR1S1PR3S1PR5S1PR4 | |
| SCHEMBL9658821 | 0.83 | S1PR1 (0.49) | DPP4S1PR1S1PR3S1PR5S1PR4 | |
| SCHEMBL9660224 | 0.83 | S1PR1 (0.49) | DPP4S1PR1S1PR3S1PR5S1PR4 | |
| SCHEMBL9660792 | 0.83 | S1PR1 (0.49) | DPP4S1PR1S1PR3S1PR5S1PR4 | |
| SCHEMBL9660886 | 0.83 | S1PR1 (0.49) | DPP4S1PR1S1PR3S1PR5S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931350-B2 | ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2021-08-04 | — | — | EP | disclosed |
| US-20190314352-A1 | ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2019-10-17 | — | — | US | disclosed |
| US-20180140589-A1 | ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2018-05-24 | — | — | US | disclosed |
| EP-2805953-B1 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2016-03-09 | — | — | EP | disclosed |
| EP-1994415-B9 | DIAGNOSIS AND PROGNOSIS OF DIPEPTIDYL PEPTIDASE-ASSOCIATED DISEASE STATES | BECTON DICKINSON CO (US) | 2015-12-16 | — | — | EP | disclosed |
| EP-1994415-B1 | DIAGNOSIS AND PROGNOSIS OF DIPEPTIDYL PEPTIDASE-ASSOCIATED DISEASE STATES | BECTON DICKINSON CO (US) | 2015-07-29 | — | — | EP | disclosed |
| EP-1586571-B3 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2015-06-24 | — | — | EP | disclosed |
| US-8906901-B2 | Administration of dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-09 | — | — | US | disclosed |
| EP-1828192-B1 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-03 | — | — | EP | disclosed |
| EP-2805953-A1 | Dipeptidyl peptidase inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2014-11-26 | — | — | EP | disclosed |
| WO-2005016911-A1 | 4-PYRIMIDONE DERIVATIVES AND THEIR USE AS PEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-02-24 | — | — | WO | disclosed |
| EP-1506967-A1 | Dipeptidyl peptidase inhibitors | Syrrx, Inc. (US) | 2005-02-16 | — | — | EP | disclosed |
| US-20050004117-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-01-06 | — | — | US | disclosed |
| US-20040259870-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2004-12-23 | — | — | US | disclosed |
| US-20040254226-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2004-12-16 | — | — | US | disclosed |
| WO-2004103993-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | SYRRX, INC. (US) | 2004-12-02 | — | — | WO | disclosed |
| US-20040242566-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2004-12-02 | — | — | US | disclosed |
| US-20040242568-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2004-12-02 | — | — | US | disclosed |
| WO-2004087053-A9 | DIPEPTIDYL PEPTIDASE INHIBITORS | SYRRX INC (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004087053-A2 | DIPEPTIDYL PEPTIDASE INHIBITORS | SYRRX, INC. (US) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004117-A1 | Dipeptidyl peptidase inhibitors | DPP9, DPP4, DPP3 | DPP4 2/4885DPP7 4/4885DPP8 5/4885 |
| US-20040254226-A1 | Dipeptidyl peptidase inhibitors | DPP3, DPP4, DPP7 | DPP4 2/4885DPP7 3/4885DPP8 5/4885 |
| US-20180140589-A1 | ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS | DPP4, DPP7, DPP3 | DPP4 1/4885DPP7 2/4885DPP8 5/4885 |
| US-20190314352-A1 | ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS | DPP4, DPP7, DPP3 | DPP4 1/4885DPP7 2/4885DPP8 5/4885 |
| US-20040242566-A1 | Dipeptidyl peptidase inhibitors | DPP9, DPP3, DPP4 | DPP4 3/4885DPP7 4/4885DPP8 5/4885 |
| US-20040242568-A1 | Dipeptidyl peptidase inhibitors | DPP9, DPP4, DPP3 | DPP4 2/4885DPP7 4/4885DPP8 5/4885 |
| US-20040259870-A1 | Dipeptidyl peptidase inhibitors | DPP9, DPP4, DPP3 | DPP4 2/4885DPP7 4/4885DPP8 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.